Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Natalizumab (Primary) ; Methylprednisolone; Prednisolone
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 02 Feb 2018 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.
- 02 Feb 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Dec 2019.
- 10 Jun 2017 Biomarkers information updated